Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Ocera Therapeutics
About
Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.
- Palo Alto,California,United States
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $35.50M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Stock Symbol
- nasdaq:OCRX
- Legal Name
- Ocera Therapeutics, Inc.
- Also Known As
- TRANZYME INC.,Renovia Inc
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 3, 2015 | Post-IPO Debt | $20M | 3 | — | — | Detail |
| Nov 6, 2013 | Post-IPO Equity | $28M | 8 | — | — | Detail |
| Mar 30, 2012 | Post-IPO Debt | $1.50M | — | — | — | Detail |
| Apr 4, 2011 | IPO | $54M | — | — | — | Detail |
| Feb 20, 2008 | Series C | $35.50M | 9 |
Greenspring Associates
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sofinnova Investments
|
Yes | Series B |
|
Greenspring Associates
|
— | Post-IPO Debt |
|
|
— | Post-IPO Debt |
Silicon Valley Bank
|
— | Post-IPO Debt |
Deerfield Partners
|
— | Post-IPO Equity |
Great Point Partners
|
— | Post-IPO Equity |
InterWest Partners
|
— | Post-IPO Equity |
QVT Financial
|
— | Post-IPO Equity |
RA Capital Management
|
— | Post-IPO Equity |
Three Arch Partners
|
— | Post-IPO Equity |
Employee Profiles
